Teknova and Pluristyx Launch Proprietary PluriFreeze™ Cryopreservation System to Accelerate the Development of Cell Therapies

Core Insights - Teknova and Pluristyx have launched the PluriFreeze cryopreservation system, which is exclusively available through Teknova, aimed at enhancing the manufacturing process of allogeneic cell therapies [1][2] Company Overview - Teknova is a leading producer of critical reagents for the life sciences industry, focusing on the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics [1][5] - Pluristyx specializes in induced Pluripotent Stem Cells (iPSCs) and innovative technologies that aim to shorten the development lifecycle of cell therapies [1][6] Product Details - The PluriFreeze system is entirely synthetic and animal-origin-free, consisting of PluriFreeze Base, a cellular wash that mimics intracellular space, and PluriFreeze PF10, a low viscosity freezing medium with 10% dimethyl sulfoxide (DMSO) [2] - The system is designed to streamline the development and commercialization of next-generation allogeneic cell therapies, providing metabolic support and simplifying scale-up processes [2][3] Pricing and Availability - Research-grade PluriFreeze Base is priced at $240 per 100 mL, while PluriFreeze PF10 is priced at $260 per 100 mL [3] - Custom formulations and GMP-grade versions are available upon request, with free product samples offered until March 21, 2025 [3] Strategic Collaboration - The collaboration between Teknova and Pluristyx allows for better control and optimization of biopreservation conditions, enhancing the viability and functionality of cells throughout the product lifecycle [3]